Home / Business and Economy / Edwards Lifesciences Predicts Strong 2026 Profit
Edwards Lifesciences Predicts Strong 2026 Profit
11 Feb
Summary
- Company forecasts 2026 profit exceeding analyst expectations.
- Sales of artificial heart valves saw a 12% increase.
- New products are expected to drive growth later in 2026.
Edwards Lifesciences has projected its 2026 profit will surpass analyst estimates, signaling confidence fueled by robust demand for its medical devices, particularly artificial heart valves. The California-based company's shares saw a 3% increase in after-hours trading following the announcement.
CEO Bernard Zovighian expressed increased confidence in the company's 2026 outlook, citing strong fourth-quarter performance and multiple upcoming catalysts. He highlighted that new product introductions are anticipated to be significant growth drivers later in 2026. This strategic focus supports the company's existing forecast of achieving an 8% to 10% sales growth rate.
In the recent quarter, sales of Edwards' primary product, the transcatheter aortic valve replacement device, rose by 12% to $1.16 billion. This figure exceeded the compiled market estimates of $1.13 billion. The company's total quarterly revenue was reported at $1.57 billion, also topping projections of $1.55 billion.
